Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 640 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Transfusion Clear all
Terminated Phase 3 Interventional Results available

CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1)

NCT04348656
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent plasma
Biological
Lead sponsor
Hamilton Health Sciences Corporation
Other
Eligibility
16 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Brooklyn, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome

NCT01584531
View directory record Official record
Conditions
Myelodysplastic Syndrome, MDS, Trisomy 8
Interventions
rigosertib
Drug
Lead sponsor
Traws Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
5
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Not applicable Interventional

Neonatal Resuscitation With Intact Cord

NCT02231411
View directory record Official record
Conditions
Intraventricular Hemorrhage
Interventions
V-DCC, Delayed cord clamping, Dry and and if apneic initially can stimulate by gently rubbing the back for approximately 30 seconds with warm sterile towels
Procedure
Lead sponsor
Sharp HealthCare
Other
Eligibility
23 Weeks to 31 Weeks
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Not applicable Interventional

Epsilon-Aminocaproaic Acid to Reduce the Need for Blood Transfusions During and Following Spine Surgery

NCT00320619
View directory record Official record
Conditions
Scoliosis, Kyphosis, Lordosis, Spondylitis, Spinal Stenosis
Interventions
Epsilon-Aminocaproic Acid (EACA), Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2016 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reproductive Capacity and Iron Burden in Thalassemia

NCT02308904
View directory record Official record
Conditions
THALASSEMIA MAJOR
Interventions
Blood Draw/Semen Exam, Retrospective data/Chart Review/Relevant Clinical Results, Pituitary MRI
Other
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
12 Years and older
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Tranexamic Acid for Reducing Blood Loss and Blood Transfusion After Periacetabular Osteotomy

NCT02253810
View directory record Official record
Conditions
Dysplasia, Congenital Hip
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
12 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)

NCT02269280
View directory record Official record
Conditions
Leukemia
Interventions
Azacitidine (AZA) Days 1 - 3, Decitabine (DAC), Best Supportive Care (BSC), Azacitidine (AZA) Days 1 - 5
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
6
States / cities
Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Intravenous EACA on Blood Loss and Transfusion Requirements After Bilateral VRO

NCT02257580
View directory record Official record
Conditions
E-Aminocaproic Acid, Bilateral Varus Rotational Osteotomy
Interventions
E-Aminocaproic acid
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
1 Year to 18 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Results available

Biotin-RBC Transfusion in SCD

NCT04426591
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Biotin Labeled Red Blood Cells, Pathogen-reduced Biotin Labeled Red Blood Cells
Drug · Device
Lead sponsor
Marianne Yee
Other
Eligibility
2 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of ECO Conversion System For Red Blood Cells.

NCT00261274
View directory record Official record
Conditions
Anemia
Interventions
A-ECO, Saline
Biological
Lead sponsor
Velico Medical
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
6
States / cities
New Haven, Connecticut • Minneapolis, Minnesota • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 22, 2026, 2:17 AM EDT
Completed No phase listed Observational

Study of Transfusion-Transmitted Infections

NCT00023023
View directory record Official record
Conditions
Viral Disease, Blood Donation, Transfusion-Transmitted Infections
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
1,771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 2:17 AM EDT
Terminated Not applicable Interventional

Trial of Feedback on Blood Use

NCT02232568
View directory record Official record
Conditions
Compliance With Restrictive RBC Transfusion Guideline
Interventions
Feedback
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
Not listed
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia

NCT02604433
View directory record Official record
Conditions
Erythrocyte Transfusion, Beta-Thalassemia
Interventions
Luspatercept, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Los Angeles, California • Oakland, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Not applicable Interventional

Rotational Thromboelastometry Activated Transfusion In Trauma Trial

NCT03765866
View directory record Official record
Conditions
Trauma
Interventions
Thromboelastometry guided transfusion
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
14 Years to 100 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed

NCT01098266
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
NGR-hTNF plus Best Investigator's Choice (BIC), Placebo plus Best Investigator's Choice (BIC)
Drug
Lead sponsor
AGC Biologics S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
7
States / cities
Corona, California • Duarte, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 22, 2026, 2:17 AM EDT
Not listed Early Phase 1 Interventional

Plasmapheresis for Treatment of Age-Related Frailty

NCT05054894
View directory record Official record
Conditions
Age-Related Frailty
Interventions
Therapeutic Plasma Exchange (TPE)
Other
Lead sponsor
Neurological Associates of West Los Angeles
Other
Eligibility
50 Years to 95 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 22, 2026, 2:17 AM EDT
Completed No phase listed Observational

Transfusion-Associated Microchimerism in Individuals Receiving a Blood Transfusion After a Traumatic Injury

NCT00400192
View directory record Official record
Conditions
Chimerism, Blood Transfusion, Wounds and Injuries
Interventions
Not listed
Lead sponsor
Vitalant Research Institute
Other
Eligibility
12 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2013 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Not applicable Interventional

Fractionated Stem Cell Infusions in Myeloma Patients Undergoing Autologous Stem Cell Transplant

NCT01416246
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Fractionated Stem Cell Infusions
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2016 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes

NCT00003138
View directory record Official record
Conditions
Anemia, Myelodysplastic Syndromes
Interventions
Erythropoietin, Filgrastim, Transfusion
Biological · Procedure
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2014
U.S. locations
28
States / cities
Denver, Colorado • Chicago, Illinois • Peoria, Illinois + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Phase 1 Interventional

Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study

NCT02287558
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia, Idiopathic Vascular Ectasia
Interventions
Pomalidomide
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 15, 2020 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

NCT03096782
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chemotherapy-Related Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Langerhans Cell Histiocytosis, Minimal Residual Disease, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Myelodysplastic Syndrome, Small Lymphocytic Lymphoma, Therapy-Related Myelodysplastic Syndrome
Interventions
Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide, Filgrastim-sndz, Fludarabine, Melphalan, Mycophenolate Mofetil, Rituximab, Tacrolimus, Total-Body Irradiation, Umbilical Cord Blood Transplantation
Biological · Drug · Radiation + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia and Unsatisfactory Response Oral Iron Under Study Protocol 1VIT17044

NCT04269707
View directory record Official record
Conditions
Iron Deficiency Anemia
Interventions
Ferric carboxymaltose
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
1 Year to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Miami, Florida • Miami Springs, Florida
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 22, 2026, 2:17 AM EDT
Terminated Not applicable Interventional Results available

Cerebral Oximetry in Single Lung Ventilation Thoracic Surgery

NCT01866657
View directory record Official record
Conditions
Hypoxia
Interventions
Vasoconstrictor Agents, Head/neck repositioning, Increase ETCO2, IV fluid bolus, Additional anesthesia, RBC transfusion, Increase FiO2
Drug · Other · Biological
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
65 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Oct 22, 2026, 2:17 AM EDT
Completed No phase listed Observational

Long Term Effects of Erythrocyte Lysis

NCT00842621
View directory record Official record
Conditions
Sickle Cell Disease, Hemolytic Anemia
Interventions
Clinical Evaluations, Laboratory Studies
Procedure · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 22, 2026, 2:17 AM EDT